Cytokine production by CD4+ T-cells responding to antigen presentation by melanoma cells

Melanoma Research

Volumn 9, Issue 2, 1999, Pages 173-180

  Brady, M S ^a   Eckels, D D ^b   Lee, F ^a   Ree, S Y ^a   Lee, J S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Blood Res Inst SE Wisconsin   (United States)

Author keywords

CD4+ T cells; HLA class Ilinterleukin 10; Interferon; Melanoma

Indexed keywords

CYTOKINE; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; INTERLEUKIN 10; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; ARTICLE; CELL CLONING; CELL PROLIFERATION; CYTOKINE PRODUCTION; HLA SYSTEM; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; MELANOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

EID: 0032799369     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199904000-00010     Document Type: Article

References (37)

1. Radka SF, Charron DJ, Brodsky FM. Class II molecules of the major histocompatibility complex considered as differentiation markers. Hum Immunol 1986; 16: 390-400.
2. Noelle R, Krammer PH, Ohara J, et al. Increased expression of Ia antigens on resting B cells: an additional role for B-cell growth factor. Proc Natl Acad Sci USA 1984; 81: 6149-6153.
3. Roehme NW, Leihson HJ, Zlotnik A, et al. Interleukin-induced inerease in Ia expression by normal mouse B cells. J Exp Med 1984; 160: 679-694.
4. Brooks A, Hartley S, Kjer-Nielsen L, et al. Class II-restricted presentation of an endogenously derived immunodominant T-cell determinant of hen egg lysozyme. Proc Natl Acad Sci USA 1991; 88: 3290-3294.
5. Chicz RM, Urban RG, Gorga JC, et al. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993; 178: 27-47.
6. Malnati MS, Marti M, La Vaute T, et al. Processing pathways for presentation of cytosolic antigen to MHC class II-restricted T cells. Nature 1992; 357: 702-704.
7. Nuchtern JG, Biddo WE, Klausner RD. Class II MHC molecules can use the endogenous pathway of antigen presentation. Nature 1990; 343: 74-76.
8. Fossati G, Anichini A, Taramelli D, et al. Immune response to autologous human melanoma: implication of class I and II MHC products. Biochim Biophys Acta 1986; 865: 235-251.
9. Wilson BS, Indiveri F, Pellegrino MA, et al. DR (Ia-like) antigens on human melanoma cells. Serologic detection and immunochemical characterization. J Exp Med 1979; 149: 658-668.
10. Winchester RJ, Wang C-Y, Gibofsky A, et al. Expression of Ia-like antigens on cultured human malignant melanoma cell lines. Proc Natl Acad Sci USA 1978; 75: 6235-6239.
11. Moretti S, Massobrio R, Brogelli L, et al. Ki67 antigen expression correlates with tumor progression and MHC-DR antigen expression in melanocytic lesions. J Invest Dermatol 1990; 95: 320-324.
12. Ruiter DJ, Bergman W, Welvaart K, et al. Immunohisto-chemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. Cancer Res 1984; 44: 3930-3935.
13. van Vreeswijk H, Ruiter DJ, Brocker E-B, et al. Differential expression of HLA-DR, DQ, and DP antigens in primary and metastatic melanoma. J Invest Dermatol 1988; 90: 755-760.
14. Brocker EB, Suter L, Sorg C. HLA-DR expression in primary melanoma of the skin. J Invest Dermatol 1984; 82: 244-247.
15. van Duinen SG, Ruiter DJ, Broecker EB, et al. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 1988; 48: 1019-1025.
16. Zaloudik J, Moore M, Ghosh AK, et al. DNA content and MHC class II antigen expression in malignant melanoma: clinical course. J Clin Pathol 1988; 41: 1078-1084.
17. Brady MS, Eckels DD, Ree SY, et al. MHC class II mediated antigen presentation by melanoma cells. J Immunother 1996; 19: 387-397.
18. Alexander MA, Bennicelli J, Guerry D IV. Defective antigen presentation by human melanoma cell lines cultured from advanced, but not biologically early disease. J Immunol 1989; 142: 4070-4078.
19. Bal V, McIndoe A, Denton G, et al. Antigen presentation by keratinocytes induces tolerance in human T cells. Eur J Immunol 1990; 20: 1893-1897.
20. Decker JC, Brabletz T. Czerny C, et al. Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4+ human T cell clone by the autologous MHC class II + melanoma. Int Immunol 1993; 5: 1501-1508.
21. Gaspari AA, Jenkins MK, Katz SI. Class II MHC-bearing keratinocytes induce antigen-specific unresponsiveness in hapten-specific TH1 clones. J Immunol 1988; 141: 2216-2220.
22. Wolf SP, Sieburth D, Sypek J. Interleukin 12: a key modulator of immune function. Stem Cells 1994; 12: 154-168.
23. Lamb JR, Eckels DD, Lake P, et al. Human T-cell clones recognize chemically synthesized peptides of influenza haemagglutinin. Nature 1982; 300: 66-69.
24. Rosen-Bronson S, Johnson AH, Hartzman RJ, et al. Human allospecific TLCs generated against HLA antigens associated with DR1 through DRw8. Immunogenetics 1986; 23: 368-378.
25. Lampson LA, Levy R. Two populations of Ia-like molecules on a human B cell line. J Immunol 1980; 125: 293-299.
26. Strohal R, Marberger K, Pehamberger H, et al. Immunohistological analysis of anti-melanoma host responses. Arch Dermatol Res 1994; 287: 28-35.
27. Grabbe S, Bruvers S, Beissert S, et al. Interferon-gamma inhibits tumor antigen presentation by epidermal antigen-presenting cells. J Leukocyte Biol 1994; 55: 695-701.
28. Hagenbaugh A, Sharma S, Dubinett SM, et al. Altered immune responses in interleukin 10 transgenic mice. J Exp Med 1997; 185: 2101-2110.
29. Groux H, Bigler GH, de Vries JE, et al. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med 1996; 184: 19-29.
30. Beissert S, Ullrich SE, Hosoi J, et al. Supernatants from UVB radiation-exposed keratinocytes inhibit Langerhans cell presentation of tumor-associated antigens via IL-10 content. J Leukocyte Biol 1995; 58: 234-240.
31. Li J, Yang Y, Inoue H, Mori M, et al. The expression of costimulatory molecules CD80 and CD86 in human carcinoma cell lines: its regulation by interferon gamma and interleukin-10. Cancer Immunol Immunother 1996; 43: 213-219.
32. Yue FY, Dummer R, Geertsen R, et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-I molecules. Int J Cancer 1997; 71: 630-637.
33. Dummer W, Becker JC, Schwaaf A, et al. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 1995; 5: 67-68.
34. Kang K, Hammerberg C, Meunier L, et al. CD11b+ macrophages that infiltrate human epidermis after in vivo ultraviolet exposure potently produce IL-10 and represent the major secretory source of epidermal IL-10 protein. J Immunol 1994; 153: 5256-5264.
35. Brunda MJ, Luistro L, Warrier R, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178: 1223-1230.
36. Trinchieri G. Interleukin-12 and its role in the generation of TH1 cells. Immunol Today 1993; 14: 335-338.
37. Gajewski TF, Pinnas M, Wong T. et al. Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations. J Immunol 1991; 146: 1750-1758.